These results highlighting the potential of T cell-based immunotherapies targeting selected HERV-K–derived epitopes as a novel approach for ovarian cancer.
ErVimmune has developed a multi-epitope cancer vaccine, ErVac01, based on an heterologous prime/boost regimen composed of adenovirus and MVA (REITHERA), with already positive interaction with FDA during an Initial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) meeting and ANSM Agence nationale de sécurité du médicament et des produits de santé during GIO meeting
